Practical insights on life sciences operations, biotech development strategy, program management, venture capital, and scientific communication, written by practitioners who have done the work across Novartis, Biogen, Editas Medicine, and Tessera Therapeutics.
Every article is written from direct industry experience, not theory. Browse by topic or read across all categories to build a fuller picture of what operationally excellent biotech looks like.
Development roadmaps, competitive positioning, portfolio optimization, and turning scientific insight into a business decision that holds up in front of investors and regulators.
Cross-functional timelines, program governance frameworks, vendor management, stage-gate reviews, and the execution infrastructure that keeps drug development programs on schedule.
How early-stage biotech companies access senior operational leadership without a full-time hire, and how to evaluate whether fractional support is right for your stage and structure.
Building messaging frameworks that work for investors, regulators, KOLs, and partners. Regulatory writing as a strategic asset. Measuring the impact of your communication strategy.
Supporting academic scientists and early venture teams as they transition from lab to industry, demystifying the ecosystem, building confidence, and developing the next generation of biotech leaders.
The discipline of integrating CMC, nonclinical, regulatory, and clinical workstreams into a coherent, milestone-driven plan, from first-in-human filing through regulatory submission.
Academic environments develop deep scientific expertise, but what is often missing is exposure to how decisions are made by investors, industry partners, and regulators. Here is how we help bridge that gap through teaching, coaching, and mentoring.
Three real-world engagements from BioVertex's portfolio: business development for an AI-enabled protein design company, venture coaching for academic spinouts, and operational diligence for a VC firm pre-close. Plus the key takeaway from each.
How to build a communications strategy that works for regulators, investors, KOLs, and partners simultaneously. Covers messaging frameworks, audience segmentation, regulatory writing, and how to measure whether your communications are actually working.
A practical guide to fractional leadership for biotech startups: how it differs from full-time hiring and traditional consulting, the six scenarios where it works best, and how to evaluate whether a fractional leader has the right experience for your stage.
What program management in biotech actually means, the hidden cost of delaying it, the six triggers that signal it is time to bring in a PM, and how to get started without over-engineering your process at an early stage.
How to build an integrated drug development timeline across CMC, nonclinical, regulatory, and clinical workstreams. Covers the real cost of timeline failures, six common pitfalls, and how to tailor timeline formats for boards, project teams, and investors.
Five trends reshaping biotech, pharma, and medtech: AI and data-driven development, cell and gene therapies, talent shortages, portfolio optimization, and digital transformation, and what each means for how companies build and manage their programs.
Our blog shares what we know. Our consulting delivers what you need. Let's discuss how BioVertex can support your organization.
Book a Free Consultation